Nitric oxide synthase 1 inhibits the progression of esophageal cancer through interacting with nitric oxide synthase 1 adaptor protein

Figure 1 Expression of nitric oxide synthase 1 in different tissues and Kaplan-Meier analysis. A: Expression of nitric oxide synthase 1 (NOS1) in different tumor tissues and normal tissues; B: Expression of NOS1 in esophageal cancer tissues (left) and normal esophageal tissues (right); C: Relationship between the expression of NOS1 and overall survival of patients with esophageal cancer. ^bP < 0.01. ^cP < 0.001. ACC: Adrenocortical cancer; BLCA: Bladder cancer; BRCA: Breast cancer; CESC: Cervical cancer; CHOL: Bile duct cancer; COAD: Colon cancer; DLBC: Large B-cell lymphoma; ESCA: Esophageal cancer; GBM: Glioblastoma; HNSC: Head and neck cancer; HNSC-HPV: Head and neck cancer-human papillomavirus; KICH: Kidney chromophobe; KIRC: Kidney clear cell carcinoma; KIRP: Kidney papillary cell carcinoma; LAML: Acute myeloid leukemia; LGG: Lower grade glioma; LIHC: Liver cancer; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian cancer; PAAD: Pancreatic cancer; PCPG: Pheochromocytoma and paraganglioma; PRAD: Prostate cancer; READ: Rectal cancer; SARC: Sarcoma; SKCM: Melanoma; STAD: Stomach cancer; TGCT: Testicular cancer; THCA: Thyroid cancer; THYM: Thymoma; UCEC: Endometrioid cancer; UCS: Uterine carcinosarcoma; UVM: Ocular melanomas; TPM: Transcripts per million; NOS1: Nitric oxide synthase 1; HR: Hazard ratio.